FMMU is one of China’s military medical universities and research centers which aims to advance military medicine.
Biostar chairman and CEO Ronghua Wang said Biostar will work with FMMU to share ideas and carry-out Phases I to IV of clinical trials for products covered under the agreement.
"We are proud to be one of only nine pharmaceutical companies in China selected to cooperate with FMMU," Wang added.
"Biostar is smaller, but our vertically integrated business model, our strong R&D, and our manufacturing and marketing capabilities were several of the reasons why Biostar was included in this group."